

Oregon Prescription Drug Monitoring Program Advisory Commission

July 19, 2013 Meeting Agenda

1:00 PM to 4:00 PM

Portland State Office Building

800 NE Oregon Street, **Room 710**

Portland, OR 97232

ATTENDEES

Advisory Commission Present: Michael Millard, Chris Apgar, Lindsay Jenkins, Teresa Keane, Sara Love, Larissa Jeffreys, Theresa Muday, John Mcilveen, Karen Wheeler

Advisory Commission Absent: Al Turner, Mark Williams, Bill Jordan

OHA Staff: Lisa Millet, Todd Beran, Heidi Murphy, Tom Burns

Guests: Fri Ngu, Danielle Sobel

Decisions
1. The meeting minutes from April 2013 were approved as drafted.

Action Items	Assigned	Status
1. Consult with the DOJ regarding whether or not a provider or pharmacist can appoint more than one delegate.	Beran	
2. Schedule the Rules Advisory Committee to meet on Friday, August 16, 2013 – send invite to PDMP Advisory Commission members.	Beran	

INTRODUCTIONS

Millard called the meeting to order at 1:10 p.m. Attendees introduced themselves.

OLD BUSINESS

a. Review of 4/26/2013 meeting minutes

The meeting minutes were reviewed and approved as written.

NEW BUSINESS

a. Review monthly and YTD metrics

Beran gave an overview of the monthly and to-date reports. He noted that new accounts for pharmacists are increasing at a greater rate than any other discipline. Queries by

pharmacists have increased significantly as well driving overall system use numbers up. The increase is due to the large chain pharmacies beginning to require sign up and use of the system – e.g. Walgreens and Walmart.

b. Review SB 470

Millard led members through a discussion of the legislative changes in Senate Bill 470. Changes include: the collection of additional data points (patient sex, days supplied, and refill data), prescriber or pharmacist ability to authorize delegate access to members of staff, prescriber ability to review prescriptions dispensed under their own DEA number, State Medical Examiner and designee access to PDMP data for autopsies and death investigations, ability for prescribers in WA, ID, and CA who treat Oregonians to access the Oregon PDMP, the use de-identified PDMP data by public health authorities, and public records nondisclosure expansion to include system user information.

Apgar inquired about potential pushback regarding out-of-state prescriber accessing the system for free from the providers and pharmacists who are paying for the system. Millet stated that a registration fee for out-of-state users is being review by the Oregon Department of Justice (DOJ).

Members discussed the importance of collecting patient sex information related to aggregate data analysis to help improve the health of Oregonians.

Members noted the need for education and training regarding delegate accounts and the responsibility of those system users authorizing delegates. Keane asked if the statute indicates that a provider or pharmacist can only appoint one delegate since the legislation states the ability to authorize disclosure to a member of staff. The program will consult with the DOJ for a determination – see Action Item 1. Apgar suggested configuring the system so that delegate accounts that are inactive for 6 months are deactivated to prevent accounts from accumulating due to staffing changes. Members suggested that rules should state that a delegate must choose the authorizing provider they are running the report for prior to conducting a query.

c. Discuss schedule for rules changes

Beran stated that in order for administrative rules to be in place prior to January 1, 2014 when the new PDMP legislation is effective, the rulemaking documents must be submitted to the Secretary of State's Office in October 2013. As such, he will schedule a meeting of the Rules Advisory Committee (RAC) on August 16. The RAC will be comprised of the PDMP Advisory Commission. If members are unable to attend, they should designate a delegate to represent their stakeholder group. See Action Item 2. Beran noted that a public hearing on draft rules will be held to allow for public comment.

d. Provide PDMP data reports update

Beran stated that the PDMP staff are finishing up the second set of bi-annual PDMP date reports. The team is targeting distribution for the end of July 2013. The reports will cover the period from April 1, 2012 to September 30, 2012. The new reports will include some county-level geomaps and data on long-term opioid use – i.e. aggregate data on patients receiving opioids for three or more consecutive months. Members expressed reservations regarding negatively labeling populations who are in need of long-term use medications. Millet stated that the reports qualify the need for much of these medications due to legitimate medical use – i.e. chronic pain, injuries, surgery, anxiety disorders, and cancer.

e. Discuss 2013 PDMP annual report

Millet stated the annual report to the PDMP Advisory Commission will be presented at the January 17, 2014 meeting.

OPEN ISSUES

Millard asked if the PDMP Advisory Commission will be consulted regarding an interim session legislative task force related to the PDMP – specifically SB 470 amendments not carried forward in the enrolled bill: 1) allowing the Board of Pharmacy (BOP) to designate drugs of concern to be tracked by the PDMP, and 2) the ability of the program to send out alerts to system users. Millet stated she did not know. Apgar expressed concern that the BOP drug designation process moves the program away from the original intent of the legislation.

PUBLIC COMMENT

Sobel noted that pharmacists are contacting physicians regarding medications prescribed – some are asking for diagnostic codes. Love confirmed that some Walgreens and Costco pharmacists are asking for diagnostic codes. Jeffries asked if this action is being prompted by insurance companies.

NEXT MEETING DATE

The next PDMP Advisory Commission meeting will be on Friday, October 18, 2013 in room 918 at the Portland State Office Building.

ADJOURNMENT

The meeting was adjourned at 3:25 PM.